NICE, Roche Reach Deal on Breast Cancer Drug
By Michael Mezher -
Published 15 June 2017
Patients in the UK could soon get access to Roche's targeted breast cancer drug Kadcyla (trastuzumab emtansine) through the National Health Service (NHS) as early as next month, the National Institute for Health and Care Excellence (NICE) said on Thursday.
Categories: News, Europe, NICE, Biologics and biotechnology, Reimbursement
Tags: NICE, Roche, Kadcyla, Herceptin, Trastuzumab
UK's NICE Rejects Roche's Breast Cancer Drug Kadcyla, Citing Major Cost Concerns
By Louise Zornoza, RegLink News -
Published 08 August 2014
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance confirming its earlier rejection of Roche’s breast cancer drug treatment Kadcyla for National Health Service (NHS) coverage.
Categories: News, Europe, NICE, Reimbursement
Tags: NICE, Final Draft Guidance, Roche, Kadcyla, Breast Cancer, Cost